In what could end up being a deal that tops $1 billion, Merck & Co. Inc. cut a collaboration and license agreement with Janux Therapeutics to find, develop and commercialize T cell engager immunotherapies for cancer patients.
In the second half of November, Black Diamond Therapeutics Inc. gained attention from Wall Street by nominating BDTX-1535 as the firm’s development candidate for glioblastoma multiforme (GBM) and kicked off IND-enabling studies.
Scientists at Duke University School of Medicine in Durham, North Carolina, have developed a small-molecule inhibitor of the cellular stress-protective transcription factor, heat shock factor 1 (HSF1), which showed developmental promise against treatment-resistant prostate cancer and other cancers.
RSS
